Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
Authors’ response
Case Report
Case series
Editorial
Editorial Board
Erratum
Guest Editorial
Letter to Editor
Letter to the Editor
Media and News
Medial Education
Medical Education
Obituary
Opinion Article
Original Article
Retraction
Review Article
Short Communication
Systematic Review
Systemic Review
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
Authors’ response
Case Report
Case series
Editorial
Editorial Board
Erratum
Guest Editorial
Letter to Editor
Letter to the Editor
Media and News
Medial Education
Medical Education
Obituary
Opinion Article
Original Article
Retraction
Review Article
Short Communication
Systematic Review
Systemic Review
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
Authors’ response
Case Report
Case series
Editorial
Editorial Board
Erratum
Guest Editorial
Letter to Editor
Letter to the Editor
Media and News
Medial Education
Medical Education
Obituary
Opinion Article
Original Article
Retraction
Review Article
Short Communication
Systematic Review
Systemic Review
View/Download PDF
Case Report
ARTICLE IN PRESS
doi:
10.25259/IJPP_125_2025

Translate:

Phenytoin-induced ataxia: Highlighting the role of therapeutic drug monitoring and individualised dosing: A case report

Author affiliations
Department of Pharmacology, North Eastern Indira Gandhi Regional Institute of Health and Medical Sciences, Shillong, Meghalaya, India.
Department of Neurology, North Eastern Indira Gandhi Regional Institute of Health and Medical Sciences, Shillong, Meghalaya, India.
Article History
Corresponding author(s)

*Corresponding author: R. Krishnamoorthi, Department of Pharmacology, North Eastern Indira Gandhi Regional Institute of Health and Medical Sciences, Shillong, Meghalaya, India. solachristus19@gmail.com

Article tools · PDF & citations

Abstract

Phenytoin (PHT), an anti-seizure medication for generalised and focal seizures, has non-linear pharmacokinetics and a narrow therapeutic window, increasing the risk of drug interactions, toxicity and adverse effects. We report a case of an 18-year-old male patient with a known case of seizure disorder of ataxia after concomitant administration of both PHT and valproic acid. Plasma PHT level was found to be supratherapeutic at 27.06 mcg/dL. PHT was discontinued with close monitoring of patient. Our report highlights PHT toxicity resulting from interaction between PHT and valproic acid even at standard therapeutic doses. To prevent drug-related adverse events, precise dosing and routine monitoring of PHT levels are essential, especially during dosage modifications, changes in formulation or the addition of new medication. Impact of avoidable adverse drug reactions on quality of life and economic burden can be reduced through preventive integrative approaches such as personalised medicine and therapeutic drug monitoring.

Keywords

  • Cerebellar ataxia
  • Drug-drug interaction
  • Individualised dosing
  • Pharmacovigilance
  • Phenytoin toxicity
  • Valproic acid
Licence
This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-Share Alike 4.0 License, which allows others to remix, transform, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

How to cite this article: Krishnamoorthi R, Ray N, Wahlang JB, Synmon B, Sarkar C, Thangkhiew B, et al. Phenytoin-induced ataxia: Highlighting the role of therapeutic drug monitoring and individualised dosing: A case report. Indian J Physiol Pharmacol. doi: 10.25259/IJPP_125_2025

INTRODUCTION

Phenytoin (PHT) (ATC code – N03AB02) is an effective and affordable antiepileptic drug (AED), but its use is declining due to safety concerns. A recent real-world study in India found that during the initial visit, levetiracetam (41.6%), sodium valproate (15.1%) and PHT (10.7%) were the most prescribed AEDs for monotherapy.[1] Combination therapy with well-chosen AEDs is essential for treating refractory seizures or pharmacoresistant epilepsy patients where monotherapy fails. However, AED therapy often poses a risk of drug interactions, which complicates the decisions to deliver appropriate treatment. Clinically, significant interactions can occur through the induction or inhibition of drug metabolism, with AEDs such as carbamazepine and PHT inducing enzymes and valproic acid inhibiting them, affecting the plasma levels of other medications. Drug-drug interactions cause around 8% of adverse drug reactions (ADRs), which lead to medication-related harm, hospital admissions, increased healthcare costs and extended hospital stays.[2] PHT causes various adverse effects, both dose-dependent and idiosyncratic reactions. Mild PHT toxicity may cause ataxia, nystagmus, slurred speech and headache.[3] The precise prevalence of PHT- related ataxia among Indian patients is unknown and rarely reported. This unique case report describes a patient who developed ataxia from PHT toxicity, triggered by adding valproic acid to long-term PHT therapy for seizure control in a patient with schizencephaly and intellectual impairment, leading to hospitalisation.

CASE REPORT

An 18-year-old male patient came to the outpatient department of neurology with complaints of difficulty maintaining balance in a standing position and being unable to walk without support for the past 2 weeks. He was a known case of seizure disorder due to schizencephaly [Figure 1] with a co-morbid intellectual impairment. He was treated for this epilepsy with the tablet PHT 300 mg/day orally for the past 5 years. Tablet Valproate 500 mg twice daily was further prescribed as an add-on AED for seizure control for the past 1 month. On examination, the patient was conscious and orientated; nystagmus was noted bilateral, which was gaze evoked. On neurological examination, the patient’s abnormal gait was suggestive of cerebellar ataxia; further cerebellar signs were positive, bilateral, symmetrical, with plantar extensor on the right side. A rating scale of ataxia scale for the assessment and rating of ataxia (SARA) was used, which revealed a gait score of 6. Vitals were normal with a blood pressure of 130/80 mmHg and a pulse rate of 80/min. The other system examination was unremarkable. After taking informed consent, the patient was admitted as a case of drug- induced cerebellar ataxia for further evaluation to rule out other causes. Routine laboratory tests (liver function test, kidney function test [KFT], complete blood count [CBC], thyroid profile, Vitamin B12, and viral markers) were normal [Table 1]. Still, serum PHT was elevated at 27.06 mcg/mL (reference 10–20 mcg/mL) using Agilent high-performance liquid chromatography (HPLC) analysis ([Figure 2] HPLC chromatogram demonstrating serum PHT concentration of 27.06 mcg/mL, above the therapeutic reference range [10–20 mcg/mL]. Peaks represent precise quantification using Agilent HPLC analysis).

(a-c) Axial T2- weighted Magnetic Resonance Imaging (MRI) of the brain showing a unilateral grey matter-lined cleft in the left hemisphere (red arrows) extending from the cerebral cortex to the lateral ventricle, consistent with schizencephaly: (a) demonstrates the cortical cleft, (b) communication of the cleft with the lateral ventricle along with associated ventricle dilatation, (c) open-lip schizencephaly suggesting an underlying cortical malformation.
Figure 1: (a-c) Axial T2- weighted Magnetic Resonance Imaging (MRI) of the brain showing a unilateral grey matter-lined cleft in the left hemisphere (red arrows) extending from the cerebral cortex to the lateral ventricle, consistent with schizencephaly: (a) demonstrates the cortical cleft, (b) communication of the cleft with the lateral ventricle along with associated ventricle dilatation, (c) open-lip schizencephaly suggesting an underlying cortical malformation.
Table 1: Blood investigation findings in a case of phenytoin-induced ataxia.
Blood parameter Result Reference range
Haemoglobin (%) 16.2 g 13.5–17.5 g (Male)
Total WBC 6,100 mcL 4,000–11,000 mcL
Serum creatinine 0.7 mg/dL 0.6–1.3 mg/dL
Serum total bilirubin 0.4 mg/dL 0.1–1.2 mg/dL
AST (SGOT) 22 IU/dL 10–40 IU/L
ALT (SGPT) 19 IU/dL 7–56 IU/L
Free T4 0.83 ng/dL 0.8–1.8 ng/dL
TSH 4.30 mIU/L 0.4–4.5 mIU/L
Serum sodium 139 meq/L 135–145 meq/L
Serum potassium 4.28 meq/L 3.5–5.1 meq/L
Serum Vitamin B12 1915 pg/mL 200–900 pg/mL
Glucose 80 mg/dL 80–140 mg/dL
CK-MB 1.55 IU/L 0–5 IU/L

WBC: White blood cell, AST (SGOT): Aspartate aminotransferase (serum glutamic oxaloacetic transaminase), ALT (SGPT): Alanine aminotransferase (serum glutamic pyruvate transaminase), TSH: Thyroid-stimulating hormone and CK-MB: Creatine Kinase-MB

High-performance liquid chromatography (HPLC) analysis of serum phenytoin levels in a case of phenytoin-induced ataxia this figure represents the HPLC chromatogram for serum phenytoin analysis in a patient diagnosed with phenytoin-induced ataxia. The X-axis denotes retention time (in minutes), while the Y-axis represents absorbance in milli-absorbance units. The peak at 10.405 min with an area of 8685.85 corresponds to the detected phenytoin concentration, indicating elevated drug levels consistent with toxicity. Additional smaller peaks may represent metabolites or other substances present in the serum. The findings emphasise the role of therapeutic drug monitoring in preventing phenytoin toxicity and optimising individualised dosing strategies.
Figure 2: High-performance liquid chromatography (HPLC) analysis of serum phenytoin levels in a case of phenytoin-induced ataxia this figure represents the HPLC chromatogram for serum phenytoin analysis in a patient diagnosed with phenytoin-induced ataxia. The X-axis denotes retention time (in minutes), while the Y-axis represents absorbance in milli-absorbance units. The peak at 10.405 min with an area of 8685.85 corresponds to the detected phenytoin concentration, indicating elevated drug levels consistent with toxicity. Additional smaller peaks may represent metabolites or other substances present in the serum. The findings emphasise the role of therapeutic drug monitoring in preventing phenytoin toxicity and optimising individualised dosing strategies.

Management of the case was initiated, which included the stoppage of the suspected offending drug from the treatment regimen. The patient was prescribed supportive therapy. For the control of seizures, injection of levetiracetam 500 mg thrice daily and a tablet of sodium valproate 500 mg twice daily were initiated. After 1 week of the above treatment, the patient was symptomatically better and was discharged from the hospital with medication (tab valproate 500 mg twice a day and tab levetiracetam 500 mg thrice daily). The patient was asked to consult the neurologist a week after discharge from the hospital. He was counselled regarding the ADRs by the pharmacologists. He was advised to adhere to the prescribed regimen, avoid self- medication and consult the physician if such problems arise in the future. ‘Naranjo’s causality assessment scale’ score was nine, indicating a definite relationship between PHT with valproic acid exposure and ‘cerebellar ataxia’.

This table presents the results of blood investigations conducted in a patient diagnosed with PHT-induced ataxia. It includes liver and KFTs, CBC and other relevant biochemical parameters.

DISCUSSION

PHT toxicity or elevated PHT levels can be influenced by several contributing factors, including extreme age, female gender, changes in dosage or formulation and brands, concomitant medications, CYP2C9 polymorphisms and hypoalbuminemia.[4] Due to the non-linear pharmacokinetics and narrow therapeutic window (10–20 μg/mL), it can cause a range of adverse effects, including cerebellar and vestibular toxicity, leading to symptoms such as nystagmus, ataxia and dizziness, even at therapeutic or higher serum levels.[5] Our case cerebellar ataxia was a type 1 predictable ADR of moderate severity, clearly preventable and linked to PHT toxicity, with contributing factors including the patient’s young age, the introduction of valproic acid during chronic PHT use and central nervous system comorbidities such as schizencephaly, aligning with the findings of LhamuTetal. The concomitant use of valproic acid with PHT can lead to dual interactions, increasing the free fraction of PHT by displacing it from plasma protein and reducing its metabolism, potentially resulting in toxicity. The supra-therapeutic PHT levels are likely due to concurrent administration, as noted in the study conducted by Markus Joerger et al. reporting a 52.5 % increase in the free fraction of PHT after 2 weeks of combined therapy with valproic acid.[6] PHT is mainly metabolised by the CYP2C9 enzyme, with genetic variants such as *2 and *3 reducing its metabolism by 25–50% compared to *1. In India, where 1.7% of the population are poor metabolisers and 24% are intermediate metabolisers, this increases the risk of PHT toxicity at therapeutic doses, which complicates the dosing.[7,8] The Clinical Pharmacogenetics Implementation Consortium guidelines to recommend a 25% reduction in PHT maintenance doses for intermediate metabolisers and a 50% reduction for poor metabolizers.[9] Therapeutic drug monitoring (TDM) aids in diagnosing clinical toxicity, establishing individualised therapeutic ranges and assessing compliance and precise dosing in polymorphic individuals. It is typically advised to monitor serum PHT levels 7–10 days after the initiation or adjustment of concomitant medications, with follow-up every 3 months thereafter. The limitations of our study include the single case, measurement of unbound PHT levels, the concentration of PHT in tablet formulations and the assessment of metabolising genetic status.

CONCLUSION

Our report emphasises the importance of TDM and genotype-biomarker based optimal dosing, advocating for an integrated approach that includes pharmacogenomic testing, clinical decision-making and monitoring of ADR can ensure precise and safe dosing of PHT, offering the potential for personalised, safe and effective therapy.

Acknowledgments:

We extend our heartfelt gratitude to Mr. Arkie Jane for her invaluable assistance in analysing phenytoin serum levels, which significantly contributed to the findings of this study. We also wish to express our sincere appreciation to Dr. D.K. Brahma, Dr. Reuben, Dr. Bandarilin Thangkhiew, Dr. Sudeep, Dr. Diana, Dr. Pavan and Dr. Rajeshkumar for their insightful reviews and constructive feedback, which greatly enhanced the quality of this paper. Their support and expertise have been instrumental in the successful completion of this research.

Ethical approval:

The research/study was approved by the Institutional Review Board at NEIGRIHMS, approval number NEIGR/IEC/M6/F12/18, dated 11th October 2018.

Declaration of patient consent:

The authors certify that they have obtained all appropriate patient consent forms. In the form, the patients have given their consent for their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.

Conflicts of interest:

There are no conflicts of interest

Use of artificial intelligence (AI)-assisted technology for manuscript preparation:

The authors confirm that there was no use of artificial intelligence (AI)-assisted technology for assisting in the writing or editing of the manuscript and no images were manipulated using AI.

Financial support and sponsorship: Nil.

References

  1. , , , , , , et al. Demographic profile and prescribing patterns of anti-epileptic drugs in Indian epilepsy patients: Electronic medical record-based nation-wide retrospective cohort study. Cureus. 2022;14:e23676.
    [CrossRef] [Google Scholar]
  2. , , , . Drug-drug interactions and the risk of adverse drug reaction-related hospital admissions in the older population. Br J Clin Pharmacol. 2024;90:959-75.
    [CrossRef] [PubMed] [Google Scholar]
  3. , , , . Phenytoin-an anti-seizure drug: Overview of its chemistry, pharmacology and toxicology. Food Chem Toxicol. 2020;142:111393.
    [CrossRef] [PubMed] [Google Scholar]
  4. , , , . Antiseizure adverse drug reaction and associated factors among epileptic patients at Jimma Medical Center: A prospective observational study. Sci Rep. 2024;14:11592.
    [CrossRef] [PubMed] [Google Scholar]
  5. , , , , . Drug-induced cerebellar ataxia: A systematic review. CNS Drugs. 2014;28:1139-53.
    [CrossRef] [PubMed] [Google Scholar]
  6. , , , , , . Interactions of serum albumin, valproic acid and carbamazepine with the pharmacokinetics of phenytoin in cancer patients. Basic Clin. Pharmacol. Toxicol. 2006;99:133-40.
    [CrossRef] [PubMed] [Google Scholar]
  7. , , . Ataxia and seizures despite phenytoin: A case report highlighting the importance of TDM and genetic influences. Case Rep Neurol Med. 2024;2024:2888895.
    [CrossRef] [PubMed] [Google Scholar]
  8. , , , . Global distribution of functionally important CYP2C9 alleles and their inferred metabolic consequences. Hum Genomics. 2023;17:15.
    [CrossRef] [PubMed] [Google Scholar]
  9. , , , , , , et al. Clinical pharmacogenetics implementation consortium (CPIC) guideline for CYP2C9 and HLA-B genotypes and phenytoin dosing: 2020 update. Clin Pharmacol Ther. 2021;109:302-9.
    [CrossRef] [PubMed] [Google Scholar]

Article statistics


Fulltext Views
1,901

PDF downloads
3,830

Downloads

View/Download PDF
Download Citations
BibTeX
RIS
Show Sections

Indian Journal of Physiology and Pharmacology

Copyright Form


Title of the Manuscript: ________________________________________


I/We certify that I/we have participated sufficiently in the intellectual content, conception, and design of this work, or the analysis and interpretation of the data (when applicable), as well as the writing of the manuscript, to take public responsibility for it. I/We agree to have my/our name(s) listed as contributors and confirm that the manuscript represents valid work.

Each author confirms they meet the criteria for authorship as established by the ICMJE. Neither this manuscript nor one with substantially similar content under my/our authorship has been published or is being considered for publication elsewhere, except as described in the covering letter.

I/We certify that all data collected during the study is presented in this manuscript and that no data from the study has been or will be published separately. I/We agree to provide, upon request by the editors, any data/information on which the manuscript is based for examination by the editors or their assignees.

I/We have disclosed all financial interests, direct or indirect, that exist or may be perceived to exist for individual contributors in connection with the content of this manuscript in the cover letter. Sources of outside support for the project are also disclosed in the cover letter.

In accordance with open access principles, I/we grant the Journal the exclusive right to publish and distribute this work under the Creative Commons Attribution-NonCommercial-ShareAlike (CC BY-NC-SA) license. This license permits others to distribute, transform, adapt, and build upon the material in any medium or format for non-commercial purposes, provided appropriate credit is given to the creator(s). Any adaptations must be shared under the same license terms. The key elements of the CC BY-NC-SA license are:

  • BY: Credit must be given to the original creator(s).
  • NC: Only non-commercial uses of the work are permitted.
  • SA: Adaptations must be shared under the same license terms.

I/We retain academic rights to the material, and the Journal is authorized to:

  1. Grant permission to republish the article in whole or in part, with or without fee.
  2. Produce preprints or reprints and translate the work into other languages for sale or free distribution.
  3. Republish the work in a collection of articles in any mechanical or electronic format.

I/We give the rights to the corresponding author to make necessary changes as requested by the Journal, handle all correspondence on our behalf, and act as the guarantor for the manuscript.

All individuals who have made substantial contributions to the work but do not meet the criteria for authorship are named in the Acknowledgment section with their written permission. If no acknowledgment is provided, it signifies that no substantial contributions were made by non-authors.


Name of the author(s) Signature Date signed Corresponding author?
Yes/No
Yes/No
Yes/No